Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445803
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-06-01
Brief Title:
CD19CD22 CAR-T Cells in Adults With RR ALL or NHL
Sponsor:
Rong Tao
Organization:
Fudan University
Study Overview
Official Title:
A Preliminary Study to Evaluate the Safety Tolerability Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 CD19CD22 CAR-T in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkins Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study examines the safety tolerability and preliminary efficacy of anti-CD19 CD22 CAR T cells KQ-2002manufactured on-site in adults with relapsed or refractory CD19 B cell acute lymphoblastic leukemia or CD19 B cell non Hodgkin lymphoma
Detailed Description:
Patients will undergo screening leukapheresis cell collection lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by the anti-CD19 KQ-2002 CAR T cell infusion The lymphodepleting chemotherapy is administered over 3 days IV to prepare the body for the CAR T cells The CAR-T cells are infused between 2-7 days after the last dose of chemotherapy Patients will be followed for two years after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None